|
74 Companies |
|
57 Products |
|
57 Products |
|
42 Mechanisms of Action |
|
2 Trials |
|
680 News |
|
| «12345678910111213...1314» |
- Trial completion: Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis (clinicaltrials.gov) - Jul 8, 2014
P=N/A, N=24, Completed, Sponsor: Universitaire Ziekenhuizen Leuven
Recruiting --> Completed
- ||| AMG 108 / AstraZeneca
Enrollment closed: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 8, 2014
P2a, N=100, Active, not recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 4, 2014
P3, N=540, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Enrolling by invitation --> Active, not recruiting
- Trial completion, Enrollment change, Trial primary completion date: Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis (clinicaltrials.gov) - Jul 3, 2014
P=N/A, N=20, Recruiting, Sponsor: Universitaire Ziekenhuizen Leuven
Enrolling by invitation --> Active, not recruiting N=40 --> 20 | Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jul 2014
- ||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
Trial initiation date: Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Jul 2, 2014
P3, N=660, Recruiting, Sponsor: Melinta Therapeutics, Inc.
N=40 --> 20 | Recruiting --> Completed | Trial primary completion date: Jun 2013 --> Jul 2014 Initiation date: Dec 2013 --> May 2014
- |||||| Baxdela (delafloxacin) / Menarini, Melinta Therap
Enrollment open, Trial initiation date: Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Jul 2, 2014
P3, N=660, Recruiting, Sponsor: Melinta Therapeutics, Inc.
Initiation date: Dec 2013 --> May 2014 Not yet recruiting --> Recruiting | Initiation date: Dec 2013 --> May 2014
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial primary completion date: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Jul 2, 2014
P3, N=10, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Not yet recruiting --> Recruiting | Initiation date: Dec 2013 --> May 2014 Trial primary completion date: Jan 2014 --> Jun 2014
- Kenketsu Glovenin-I (normal human immunoglobulin IV) / Takeda
Trial completion, Trial primary completion date: Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. (clinicaltrials.gov) - Jul 2, 2014
P3, N=10, Completed, Sponsor: Nihon Pharmaceutical Co., Ltd
Trial primary completion date: Jan 2014 --> Jun 2014 Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014
- tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Trial primary completion date: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - Jun 18, 2014
P3, N=2900, Active, not recruiting, Sponsor: CONRAD
Recruiting --> Completed | Trial primary completion date: Jan 2014 --> Jun 2014 Trial primary completion date: May 2014 --> Aug 2014
- voriconazole / Generic mfg.
Trial suspension: Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy (clinicaltrials.gov) - Jun 18, 2014
P2, N=33, Suspended, Sponsor: Colin Lunt
Trial primary completion date: May 2014 --> Aug 2014 Not yet recruiting --> Suspended
- | tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Enrollment closed, Trial primary completion date: Safety and Effectiveness of Tenofovir Gel in the Prevention of Human Immunodeficiency Virus (HIV-1) Infection in Women and the Effects of Tenofovir Gel on the Incidence of Herpes Simplex Virus (HSV-2) Infection (clinicaltrials.gov) - Jun 18, 2014
P3, N=2900, Active, not recruiting, Sponsor: CONRAD
Not yet recruiting --> Suspended Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Aug 2014
- gentamicin sulfate / Generic mfg.
Trial initiation date: PAGELEC: WR 279,396 for the Treatment of Cutaneous Leishmaniasis (clinicaltrials.gov) - Jun 17, 2014
P2, N=30, Recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> Aug 2014 Initiation date: Sep 2013 --> Jun 2014
- voriconazole / Generic mfg.
Trial initiation date, Trial suspension: Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy (clinicaltrials.gov) - Jun 15, 2014
P2, N=33, Not yet recruiting, Sponsor: Colin Lunt
Initiation date: Sep 2013 --> Jun 2014 Initiation date: Oct 2013 --> Mar 2014 | Not yet recruiting --> Suspended
- ||||| Enrollment change: Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice (clinicaltrials.gov) - Jun 13, 2014
P3, N=403, Completed, Sponsor: Taro Pharmaceuticals USA
Initiation date: Oct 2013 --> Mar 2014 | Not yet recruiting --> Suspended N=150 --> 403
- Trial primary completion date: Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia (clinicaltrials.gov) - Jun 13, 2014
P1/2, N=80, Recruiting, Sponsor: Drugs for Neglected Diseases
N=150 --> 403 Trial primary completion date: May 2014 --> Feb 2015
- amphotericin b liposome / Generic mfg.
Trial primary completion date: LVBrasil: Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil (clinicaltrials.gov) - Jun 3, 2014
P4, N=380, Terminated, Sponsor: University of Brasilia
Trial primary completion date: May 2014 --> Feb 2015 Trial primary completion date: Jun 2014 --> Nov 2014
- amphotericin b liposome / Generic mfg.
Trial termination: LVBrasil: Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil (clinicaltrials.gov) - Jun 3, 2014
P4, N=380, Terminated, Sponsor: University of Brasilia
Trial primary completion date: Jun 2014 --> Nov 2014 Recruiting --> Terminated; DSMB recommendation based on programmed interim analysis.
- Clinical: Clinical Assessment of the Effectiveness and Safety of Herpes Patch SOS in the Treatment of Herpes Simplex Labialis in Comparison to a Competitor's Product. (clinicaltrials.gov) - Jun 3, 2014
P=N/A, N=0, Completed, Sponsor: Technische Universität Dresden
- | Ilaris (canakinumab) / Novartis
Trial primary completion date: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - Jun 2, 2014
P3, N=15, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Terminated; DSMB recommendation based on programmed interim analysis. Trial primary completion date: Apr 2015 --> Sep 2015
- || tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Trial primary completion date: Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding (clinicaltrials.gov) - Jun 2, 2014
P4, N=55, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Apr 2015 --> Sep 2015 Trial primary completion date: Dec 2013 --> Jun 2015
- ||| tenofovir vaginal gel (GS-1278 gel) / Gilead, CONRAD
Enrollment closed: Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding (clinicaltrials.gov) - Jun 2, 2014
P4, N=55, Active, not recruiting, Sponsor: University of Washington
Trial primary completion date: Dec 2013 --> Jun 2015 Recruiting --> Active, not recruiting
- cefazolin / Generic mfg., cephalexin / Generic mfg., probenecid / Generic mfg.
Trial primary completion date: Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis (clinicaltrials.gov) - May 28, 2014
P2, N=320, Recruiting, Sponsor: Kelowna General Hospital
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2011 --> Aug 2014
- Altabax (retapamulin) / GSK, Almirall
Enrollment closed: Retapamulin Microdialysis Feasibility Study (clinicaltrials.gov) - May 21, 2014
P1, N=3, Active, not recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2011 --> Aug 2014 Recruiting --> Active, not recruiting
- | CLS003 / Maruho
Biomarker, Trial completion: First-in-Human Study of CLS003 ICVT in Subjects With Cutaneous Warts (clinicaltrials.gov) - May 20, 2014
P1/2, N=12, Completed, Sponsor: Cutanea Life Sciences, Inc.
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Ilaris (canakinumab) / Novartis
Enrollment closed: Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease (clinicaltrials.gov) - May 19, 2014
P3, N=17, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Active, not recruiting
- | Olorofim (orotomide) / F2G
New P1 trial: F901318 Single Ascending Dose Study in Healthy Male Volunteers (clinicaltrials.gov) - May 18, 2014
P1, N=40, Not yet recruiting, Sponsor: F2G Ltd.
- Trial primary completion date: Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy (clinicaltrials.gov) - May 12, 2014
P4, N=31, Completed, Sponsor: Saint Joseph Mercy Health System
Recruiting --> Active, not recruiting Trial primary completion date: Sep 2013 --> Mar 2014
- Enrollment change: Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy (clinicaltrials.gov) - May 12, 2014
P4, N=31, Completed, Sponsor: Saint Joseph Mercy Health System
Trial primary completion date: Sep 2013 --> Mar 2014 N=52 --> 31
- Trial completion: Pulsed 1064nm Nd:YAG in the Treatment of Verruca Vulgaris Versus Conventional Therapy With Liquid Nitrogen Cryotherapy (clinicaltrials.gov) - May 12, 2014
P4, N=31, Completed, Sponsor: Saint Joseph Mercy Health System
N=52 --> 31 Recruiting --> Completed
- Trial primary completion date: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - May 12, 2014
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Recruiting --> Completed Trial primary completion date: Feb 2014 --> Dec 2014
- Trial completion date: Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever) (clinicaltrials.gov) - May 12, 2014
P=N/A, N=2170, Recruiting, Sponsor: University Hospital, Geneva
Trial primary completion date: Feb 2014 --> Dec 2014 Trial completion date: May 2014 --> Dec 2014
- Altabax (retapamulin) / GSK, Almirall
Trial primary completion date: Retapamulin Microdialysis Feasibility Study (clinicaltrials.gov) - May 7, 2014
P1, N=3, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: May 2014 --> Dec 2014 Trial primary completion date: May 2014 --> Jun 2014
- Altabax (retapamulin) / GSK, Almirall
Trial completion date: Retapamulin Microdialysis Feasibility Study (clinicaltrials.gov) - May 7, 2014
P1, N=3, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2014 --> Jun 2014 Trial completion date: May 2014 --> Jun 2014
- Altabax (retapamulin) / GSK, Almirall
Enrollment open: Retapamulin Microdialysis Feasibility Study (clinicaltrials.gov) - May 7, 2014
P1, N=3, Recruiting, Sponsor: GlaxoSmithKline
Trial completion date: May 2014 --> Jun 2014 Not yet recruiting --> Recruiting
- || HSV vaccine (GEN-003) / Genocea, Shionogi
Trial primary completion date: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - May 5, 2014
P1/2, N=143, Completed, Sponsor: Genocea Biosciences, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Apr 2014
- || HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion date: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - May 5, 2014
P1/2, N=143, Completed, Sponsor: Genocea Biosciences, Inc.
Trial primary completion date: Jun 2014 --> Apr 2014 Trial completion date: Jun 2014 --> Apr 2014
- ||| New P1 trial: Evaluate the Safety and Efficacy of Naftifine Hydrochloride Cream 2% and Naftin® Cream 2% in Patients With Tinea Pedis (clinicaltrials.gov) - May 5, 2014
P1, N=890, Completed, Sponsor: Taro Pharmaceuticals USA
- |||| HSV vaccine (GEN-003) / Genocea, Shionogi
Trial completion: Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine (clinicaltrials.gov) - May 5, 2014
P1/2, N=143, Completed, Sponsor: Genocea Biosciences, Inc.
Trial completion date: Jun 2014 --> Apr 2014 Active, not recruiting --> Completed
- Clinical: A Clinical Investigation to Evaluate the Safety and Performance of a Treatment Kit for Ingrowing Toenail (clinicaltrials.gov) - May 4, 2014
P=N/A, N=36, Not yet recruiting, Sponsor: Reckitt Benckiser Healthcare (UK) Limited
- albendazole / Generic mfg.
Trial initiation date: Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=16000, Recruiting, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Initiation date: Jan 2014 --> Feb 2014
- albendazole / Generic mfg.
Trial primary completion date: Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=16000, Recruiting, Sponsor: Washington University School of Medicine
Initiation date: Jan 2014 --> Feb 2014 Trial primary completion date: Dec 2016 --> Dec 2017
- albendazole / Generic mfg.
Trial completion date: Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=16000, Recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Dec 2016 --> Dec 2017 Trial completion date: Jun 2017 --> Jun 2018
- albendazole / Generic mfg.
Enrollment open: Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast) (clinicaltrials.gov) - Apr 29, 2014
P=N/A, N=16000, Recruiting, Sponsor: Washington University School of Medicine
Trial completion date: Jun 2017 --> Jun 2018 Not yet recruiting --> Recruiting
- |||||||||| Zeven (dalbavancin) / RaQualia, AbbVie
New P3 trial: Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (clinicaltrials.gov) - Apr 29, 2014
P3, N=410, Recruiting, Sponsor: Durata Therapeutics, Inc.
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J
New P1/2 trial: Topical Infliximab in Autoimmune Eyes With Keratoprosthesis (clinicaltrials.gov) - Apr 26, 2014
P1/2, N=4, Not yet recruiting, Sponsor: James Chodosh, MD, MPH
- |||| Lytixar (LTX-109) / Lytix
Trial completion: A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo (clinicaltrials.gov) - Apr 24, 2014
P2, N=210, Completed, Sponsor: Lytix Biopharma AS
Not yet recruiting --> Recruiting Recruiting --> Completed
- Enrollment change: SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma (clinicaltrials.gov) - Apr 20, 2014
P0, N=29, Completed, Sponsor: National Cheng-Kung University Hospital
Recruiting --> Completed N=40 --> 29
- | Trial completion: SR-T100 Gel Efficacy & Safety Study for Vulva Pre-cancerous Lesions & Cutaneous Condyloma (clinicaltrials.gov) - Apr 20, 2014
P0, N=29, Completed, Sponsor: National Cheng-Kung University Hospital
N=40 --> 29 Recruiting --> Completed
- ||| AMG 108 / AstraZeneca
Enrollment change: Assessment of the Safety, Tolerability and Efficacy of MEDI8968 in Subjects With Moderate to Severe Hidradenitis Suppurativa (clinicaltrials.gov) - Apr 17, 2014
P2a, N=100, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed N=150 --> 100
- ||||| ceftaroline fosamil / Generic mfg.
Enrollment closed: Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections (clinicaltrials.gov) - Apr 15, 2014
P2/3, N=270, Active, not recruiting, Sponsor: Cerexa, Inc.
N=150 --> 100 Recruiting --> Active, not recruiting